Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Total Liabilities (2016 - 2025)

Cytokinetics (CYTK) has disclosed Total Liabilities for 16 consecutive years, with $2.1 billion as the latest value for Q4 2025.

  • Quarterly Total Liabilities changed N/A to $2.1 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.1 billion through Dec 2025, changed N/A year-over-year, with the annual reading at $2.1 billion for FY2025, N/A changed from the prior year.
  • Total Liabilities for Q4 2025 was $2.1 billion at Cytokinetics, up from $2.0 billion in the prior quarter.
  • The five-year high for Total Liabilities was $2.1 billion in Q4 2025, with the low at $509.2 million in Q1 2021.
  • Average Total Liabilities over 5 years is $1.1 billion, with a median of $1.1 billion recorded in 2022.
  • The sharpest move saw Total Liabilities surged 601.6% in 2021, then increased 7.63% in 2024.
  • Over 5 years, Total Liabilities stood at $597.5 million in 2021, then soared by 87.91% to $1.1 billion in 2022, then grew by 7.84% to $1.2 billion in 2023, then increased by 19.77% to $1.4 billion in 2024, then soared by 43.74% to $2.1 billion in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $2.1 billion, $2.0 billion, and $1.6 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.